316 related articles for article (PubMed ID: 9195289)
1. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
Gradishar WJ
Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
[TBL] [Abstract][Full Text] [Related]
2. The preclinical evaluation of angiogenesis inhibitors.
O'Reilly MS
Invest New Drugs; 1997; 15(1):5-13. PubMed ID: 9195285
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
4. New strategies in anti-vascular cancer therapy.
Bloemendal HJ; Logtenberg T; Voest EE
Eur J Clin Invest; 1999 Sep; 29(9):802-9. PubMed ID: 10469169
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic tumour therapy: will it work?
Augustin HG
Trends Pharmacol Sci; 1998 Jun; 19(6):216-22. PubMed ID: 9666712
[TBL] [Abstract][Full Text] [Related]
6. Regulating angiogenesis: a new therapeutic strategy.
Gibaldi M
J Clin Pharmacol; 1998 Oct; 38(10):898-903. PubMed ID: 9807969
[TBL] [Abstract][Full Text] [Related]
7. Overview of angiogenesis: Biologic implications for antiangiogenic therapy.
Ellis LM; Liu W; Ahmad SA; Fan F; Jung YD; Shaheen RM; Reinmuth N
Semin Oncol; 2001 Oct; 28(5 Suppl 16):94-104. PubMed ID: 11706401
[TBL] [Abstract][Full Text] [Related]
8. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.
Fox SB; Harris AL
Invest New Drugs; 1997; 15(1):15-28. PubMed ID: 9195286
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
Bikfalvi A; Bicknell R
Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of antiangiogenic agents.
Twardowski P; Gradishar WJ
Curr Opin Oncol; 1997 Nov; 9(6):584-9. PubMed ID: 9370081
[TBL] [Abstract][Full Text] [Related]
11. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
12. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
13. Angiogenesis inhibitors. New anticancer strategy.
Zgodziński W; Wallner G; Dabrowski A
Pol J Pharmacol; 1999; 51(6):455-62. PubMed ID: 10817522
[TBL] [Abstract][Full Text] [Related]
14. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo.
Oikawa T; Sasaki M; Inose M; Shimamura M; Kuboki H; Hirano S; Kumagai H; Ishizuka M; Takeuchi T
Anticancer Res; 1997; 17(3C):1881-6. PubMed ID: 9216639
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
[TBL] [Abstract][Full Text] [Related]
16. Development of angiogenesis inhibitors for cancer therapy.
Eckhardt SG; Pluda JM
Invest New Drugs; 1997; 15(1):1-3. PubMed ID: 9195284
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.
Pluda JM
Semin Oncol; 1997 Apr; 24(2):203-18. PubMed ID: 9129690
[TBL] [Abstract][Full Text] [Related]
18. [Targeting angiogenesis in oncology].
Fayette J; Soria JC; Armand JP
Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic strategies and agents in clinical trials.
Rosen L
Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
[TBL] [Abstract][Full Text] [Related]
20. TNP-470 (AGM-1470): mechanisms of action and early clinical development.
Castronovo V; Belotti D
Eur J Cancer; 1996 Dec; 32A(14):2520-7. PubMed ID: 9059342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
